| |
Treatment subgroup
|
|---|
|
Adjuvant hormonal therapy
|
Yes
|
Yes
|
No
|
|
Adjuvant chemotherapy
|
No
|
Yes
|
Yes or No
|
|
Characteristics
|
RS < 25
|
RS ≥ 25
|
P
|
RS < 25
|
RS ≥ 25
|
P
|
RS < 25
|
RS ≥ 25
|
P
|
|
Total, n (%)
|
1125 (94)
|
74 (6)
|
–
|
241 (51)
|
229 (49)
|
–
|
63 (71)
|
26 (29)
|
–
|
|
Age, median (interquartile range)
|
54 (48–62)
|
65 (54–70)
|
< 0.001
|
49 (44–56)
|
54 (46–62)
|
< 0.001
|
52 (46–63)
|
53 (45–63)
|
0.96
|
|
Stage, n (%)
| | |
0.18
| | |
0.09
| | |
0.15
|
|
I
|
799 (71)
|
58 (78)
| |
153 (63)
|
162 (71)
| |
44 (70)
|
14 (54)
| |
|
II
|
326 (29)
|
16 (22)
| |
88 (37)
|
67 (29)
| |
19 (30)
|
12 (46)
| |
|
Surgery type, n (%)
| | |
0.03
| | |
0.37
| | |
0.81
|
|
Breast-conserving surgery
|
812 (72)
|
62 (84)
| |
159 (66)
|
160 (70)
| |
42 (67)
|
18 (69)
| |
|
Mastectomy
|
313 (28)
|
12 (16)
| |
82 (34)
|
69 (30)
| |
21 (33)
|
8 (31)
| |
|
Postoperative radiation, n (%)
| | |
0.84
| | |
0.86
| | |
0.59
|
|
No
|
301 (27)
|
19 (26)
| |
66 (27)
|
61 (27)
| |
30 (52)
|
14 (46)
| |
|
Yes
|
824 (73)
|
55 (74)
| |
175 (73)
|
168 (73)
| |
33 (48)
|
12 (54)
| |
|
Number of events, n
| | |
–
| | |
–
| | |
–
|
|
iLRR
|
16
|
3
| |
1
|
1
| |
1
|
0
| |
|
DM without iLRR
|
9
|
2
| |
2
|
6
| |
0
|
1
| |
|
Death without iLRR or DM
|
7
|
3
| |
0
|
2
| |
0
|
1
| |
- DM distant metastasis, iLRR isolated locoregional recurrence, RS recurrence score
